HIV and AIDS

Use this interactive map to help you determine if your state has a Section 1115 Medicaid waiver and the impact on Medicaid beneficiaries living with or at risk for HIV and hepatitis. Please see NASTAD’s related Medicaid resources: Medicaid 1115 Waivers: Considerations for HIV and Hepatitis Programs and Medicaid 1115 Waivers: Exemptions for People Living with HIV and Hepatitis. Additional information about approved and pending waivers can be found on the Centers for Medicare & Medicaid Services website.

On Thursday, December 9, HIV.gov hosted “The Updated National HIV/AIDS Strategy: What’s New and What’s Next? A Webinar on How to Use the Strategy ”, led by Harold Phillips, Director, The White House Office of National AIDS Policy (ONAP). Topics included how the Strategy can be used in communities, as well as how community-based organizations and federal officials plan to use the Strategy within their own communities and departments.

This National HIV/AIDS Strategy (the Strategy), the nation’s third national HIV strategy, updates the HIV National Strategic Plan (2021). The Strategy sets forth bold targets for ending the HIV epidemic in the United States by 2030, including a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030

Unequal, unprepared, under threat: why bold action against inequalities is needed to end AIDS, stop COVID-19 and prepare for future pandemics. Arabic.

Unequal, unprepared, under threat: why bold action against inequalities is needed to end AIDS, stop COVID-19 and prepare for future pandemics.

Recent news about HIV biomedical prevention research has been a mixed bag: very encouraging results from long-acting pre-exposure prophylaxis (PrEP) trials, but a disappointing lack of significant protection achieved with experimental HIV vaccines. Furthermore, the entire research effort has had to wrestle with the impact of the COVID-19 pandemic.

Este resumen ofrece un panorama general de la profilaxis de post-exposición (PEP) al virus VIH (virus de inmunodeficiencia humana)

This brief provides an overview of HIV Post-exposure Prophylaxis (PEP) in the southern United States (“the South”). The goal is to provide an overview of prevention with PEP to drive collective action between: Jurisdictional and local public health departments, community-based organizations (CBOs), and community health clinics, to increase and improve prevention with PEP.

The Joint United Nations Programme on HIV/AIDSUNAIDS report shows that people living with HIV face a double jeopardy, HIV and COVID-19, while key populations and children continue to be left behind in access to HIV services